Opportunistic invasive fungal infections (IFIs) emerged as common causes of death of patients with hematologic malignancies (HM) once effective antibacterial therapy reduced bacterial deaths.
In the dawn of medical mycology, timely diagnosis was difficult, and treatment was limited by toxicity of antifungals and associated with poor outcomes.
